<DOC>
	<DOCNO>NCT02916329</DOCNO>
	<brief_summary>The investigator develop [ 68Ga ] -labelling Anti-EGFR Affibody Molecule target molecular imaging agent noninvasive repeatable detect EGFR-ECD expression status .</brief_summary>
	<brief_title>In Vivo EGFR-ECD Molecular Imaging Using 68Ga- Labelling Anti-EGFR Affibody Molecule</brief_title>
	<detailed_description>The goal investigator evaluate use [ 68Ga ] -labelling Anti-EGFR Affibody Molecule novel PET/CT radiotracer monitor EGFR-ECD expression status classify EGFR-ECD benefit NSCLC patient . The investigator want evaluate use [ 68Ga ] -labelling Anti-EGFR Affibody Molecule lung cancer image adult NSCLC patient different EGFR-ECD expression status primary metastatic cancer .</detailed_description>
	<criteria>Advanced NSCLC 18 year old A life expectancy least 12 week Presence malignant lesion within chest least 0.5 cm diameter measure compute tomography ( CT ) Written informed consent Claustrophobia Pregnancy Metal implant thorax</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>